PeptideInfo
Back to Directory

Thymosin Alpha-1

Phase II Trials

Also known as: Tα1, Thymalfasin, Zadaxin

Educational Content Only

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. The FDA has not evaluated many of the peptides discussed here. Always consult a licensed healthcare provider before making any health decisions.

Overview

Thymosin Alpha-1 is an endogenous peptide derived from prothymosin alpha, produced primarily by thymic epithelial cells. It has been studied extensively for its immunomodulatory properties and is approved in several countries for use in the context of hepatitis B, hepatitis C, and as an adjunct in certain immunocompromised states.

Possible Uses

The following areas have been examined in research contexts. This does not constitute medical advice or imply proven efficacy in humans.

  • Immune Support
  • Anti-Aging & Longevity
Mechanism of Action

Research indicates Thymosin Alpha-1 may enhance T-cell maturation and differentiation, augment NK cell activity, upregulate MHC class I expression, and modulate cytokine production including interferon-gamma and interleukins. It is thought to act primarily through toll-like receptor and dendritic cell pathways.

Safety Notes

Approved in over 35 countries (as Zadaxin/thymalfasin). Generally well-tolerated with injection site reactions as the most common adverse effect. Not FDA-approved in the US.

Read More

Selected peer-reviewed papers from research literature. These are educational references only and do not imply proven efficacy or safety in humans.

Research Profile

Half-Life

~2 hours

Administration

subcutaneous injection

Legal Status (US)

Approved in multiple countries including Italy, China, and others. Not FDA-approved in the US. Available as a research chemical in the US.

222 indexed research passages

Categories
Immune & InflammationLongevity & Anti-Aging
Research Interest Areas
Immune SupportAnti-Aging & Longevity